A framework for monitoring population immunity to SARS-CoV-2

• Authors: Benjamin Lopman, Emory University; Kayoko Shioda, Emory University; Quan Nguyen, Georgia Institute of Technology; Stepehn J Beckett, Georgia Institute of Technology; Aaron Siegler, Emory University; Patrick Sullivan, Emory University; Joshua S Weitz, Georgia Institute of Technology
• Journal Title: ANNALS OF EPIDEMIOLOGY
• Volume: Volume 63
• Publisher: ELSEVIER SCIENCE INC | 2021-09-05, Pages 75-78
• Type of Work: Article | Final Publisher PDF
• Publisher DOI: http://doi.org/10.1016/j.annepidem.2021.08.013
• Subjects: Health Sciences, Epidemiology; Environmental Sciences
• Keywords: Science & Technology; Life Sciences & Biomedicine; Public, Environmental & Occupational Health; Herd Immunity; Vaccines; SARS-CoV-2; Covid-19; Serology; INFECTION

Abstract

In the effort to control SARS-CoV-2 transmission, public health agencies in the United States and globally are aiming to increase population immunity. Immunity through vaccination and acquired following recovery from natural infection are the two means to build up population immunity, with vaccination being the safe pathway. However, measuring the contribution to population immunity from vaccination or natural infection is non-trivial. Historical COVID-19 case counts and vaccine coverage are necessary information but are not sufficient to approximate population immunity. Here, we consider the nuances of measuring each and propose an analytical framework for integrating the necessary data on cumulative vaccinations and natural infections at the state and national level. To guide vaccine roll-out and other aspects of control over the coming months, we recommend analytics that combine vaccine coverage with local (e.g. county-level) history of case reports and adjustment for waning antibodies to establish local estimates of population immunity. To do so, the strategic use of minimally-biased serology surveys integrated with vaccine administration data can improve estimates of the aggregate level of immunity to guide data-driven decisions to re-open safely and prioritize vaccination efforts.